Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMC435 (Simeprevir) in Japanese Patients with Genotype 1 Chronic Hepatitis C
NCT00996476Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2009
- Primary completion
- Jan 2011
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of simeprevir in hepatitis C (HCV), sponsored by Janssen Pharmaceutical. Started Jul 2009; status: completed.
02
Drugs
simeprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00996476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00996476.